ILMN$145.3
$144.096
Chart
Performance
Key Stats
AI ILMN Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
BuyIllumina shows strong fundamental performance and significant thematic alignment in the genomics space. Technical indicators suggest a cautiously optimistic short-to-medium term outlook, with potential for further upside if key resistance levels are breached.
Thematic
Illumina is at the forefront of the genomics revolution, benefiting from advancements in personalized medicine, diagnostics, and research. These secular tailwinds are expected to drive long-term growth.
Fundamental
Illumina demonstrates robust revenue generation and a solid balance sheet. While profitability has been volatile, recent quarters show a return to positive net income, and the company's large cash reserves provide financial stability.
Technical
Illumina's stock is showing a strong upward trend on multiple timeframes. While some indicators suggest it is approaching overbought territory, the overall momentum and moving average support indicate continued strength, with potential for further gains.
| Factor | Score |
|---|---|
| Genomics & Biotechnology | 95 |
| Healthcare Innovation | 80 |
| Regulatory Landscape (Healthcare) | 65 |
| Emerging Markets Adoption | 75 |
| Competitive Moat | 95 |
| Factor | Score |
|---|---|
| Valuation | 55 |
| Profitability | 30 |
| Growth | 45 |
| Balance Sheet Health | 70 |
| Cash Flow | 75 |
| Factor | Score |
|---|---|
| Trend Analysis | 85 |
| Momentum | 65 |
| Volume Confirmation | 70 |
| Support & Resistance | 70 |
| Short-term Oscillators | 75 |
AI Investing Checklist
Powered by LiveAIBullish Points (7)
Improving EPS Trends
Recent EPS performance shows positive surprises in Q2 2025 (3.35%) and Q4 2024 (29.41%), indicating that the company is exceeding analyst expectations in certain periods.
Strong Short-Term Momentum
Short-term moving averages (10-day EMA, 10-day SMA, 20-day EMA, 20-day SMA, etc.) across multiple timeframes (1m, 5m, 15m, 30m, 1h, 2h, 4h, 1d) predominantly show 'Buy' signals, suggesting upward price momentum.
Bearish Points (7)
Negative Earnings and High P/S
Trailing P/E is not available due to negative EPS (EPS TTM of -6.08), and the Price-to-Sales (P/S) ratio for Q4 2024 was 19.2, which is high, especially considering the negative net income.
Significant Historical Losses and Volatility
The company has reported substantial net losses in recent annual periods (e.g., -$1.223 billion in 2024, -$1.161 billion in 2023) and quarterly losses (e.g., -$1.988 billion in Q2 2024), indicating significant profitability challenges.
Calendar
August 2025
1
Next Earnings Date
H: $1.05
A: $1.01
L: $0.96
H: 1.08B
A: 1.05B
L: 1.04B
Profile
Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is headquartered in San Diego, California.
Seasonals
Price Target
108.58 USD
The 39 analysts offering 1 year price forecasts for ILMN have a max estimate of 185.00 and a min estimate of 70.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 95
Direct competitor in long-read DNA sequencing technology (PacBio HiFi), offering an alternative to Illumina's short-read dominant platform, particularly for de novo assembly and complex genomic regions.
Weight: 95
Direct competitor in real-time, long-read DNA/RNA sequencing using nanopore technology, challenging Illumina's market share in various applications, from research to diagnostics.
Weight: 90
A diversified life science giant; competes with Illumina through its Ion Torrent sequencing platform and offers a vast array of lab instruments, reagents, and consumables essential for genomic research and diagnostics.
Weight: 88
A global science and technology innovator with a strong presence in life sciences (e.g., Beckman Coulter, Cytiva, Leica Biosystems), providing instruments, consumables, and services that are critical for molecular and genomic workflows, often complementary to or competitive with Illumina's offerings.